Promising Results in Phase 1 Clinical Trial for Immunotherapeutic Treatment of Parkinson’s Disease
A recent phase 1 clinical trial has shown promising results in the development of a new immunotherapeutic treatment for patients with Parkinson’s disease. The study focused on the investigational drug UB-312 targeting pathological α-synuclein (αSyn) and assessed safety, tolerability, and immunogenicity. Results indicate that UB-312 was well-tolerated, with most adverse events being mild and transient. The treatment demonstrated immunogenicity and showed an increase in anti-αSyn antibody titers over the course of the study. While no significant differences in clinical scales were observed between the treatment and placebo groups, the study suggests potential for UB-312 to slow down or halt disease progression in Parkinson’s patients.